双轮驱动、深耕非洲：尔康制药海外战略布局初显成效

Group 1 - The company expects a net profit attributable to shareholders of between -325 million to -385 million yuan for the fiscal year 2025, primarily impacted by asset impairment losses [1] - The company's main business has shown steady growth compared to the same period last year, benefiting from the operation of the lithium ore beneficiation plant project in Nigeria, with lithium concentrate business generating over 200 million yuan in revenue [1] - The cash flow from operating activities remains robust, with a significant increase in net cash flow from operating activities compared to the same period last year, indicating healthy operations [1] Group 2 - The company is deepening its industrial layout in Africa by investing a total of 18 million USD in comprehensive formulation and injection production projects in Tanzania and Nigeria, which is expected to broaden its business reach and create new profit growth points [2] - The ongoing deepening of China-Africa cooperation provides significant opportunities for Chinese companies to expand overseas, aligning with the company's strategy to enhance its presence in the African renewable energy and healthcare sectors [2] - The company is solidifying its long-term development foundation as mining project capacities are released and pharmaceutical manufacturing bases are established, with future performance expected to return to a growth trajectory [2]